Paper Details

  1. Home
  2. Paper Details

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Author: , BoninoF, BrunettoM R, DiagoM, FarciP, GermanidisG, GurelS, HadziyannisS, JinR, LaiM-Y, LauG K K, MarcellinP, McCloudP, PiratvisuthT, PopescuM, YurdaydinC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy of peginterferon alpha-2a with or without lamivudine to lamivudine alone in treating HBeAg-negative chronic hepatitis B, finding that the combination therapy was more effective.
Paper Details　
Original Abstract of the Article :
In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942152/

データ提供：米国国立医学図書館（NLM）

Predicting Response to Hepatitis B Treatment: Uncovering the Secrets of the Desert

The field of hepatology is constantly seeking effective treatments for chronic hepatitis B, a viral infection that can lead to serious liver damage. This study explores the effectiveness of peginterferon alpha-2a and lamivudine, two commonly used antiviral medications, in patients with HBeAg-negative chronic hepatitis B. The researchers investigated the factors that predict response to these treatments.

A Guide Through the Desert: Predicting Treatment Response

This study offers valuable insights into the factors that influence treatment response in patients with HBeAg-negative chronic hepatitis B. The researchers found that certain pre-treatment factors, like the presence of certain genetic markers or the severity of liver damage, were associated with higher response rates to peginterferon alpha-2a with or without lamivudine. This information can help clinicians make more informed treatment decisions, tailoring therapy to individual patient characteristics. It's like having a skilled guide to navigate the vast and unpredictable desert of chronic hepatitis B, ensuring that patients receive the most effective treatment.

Tailoring Treatment to Individual Needs: A Key to Success

This study underscores the importance of personalized medicine in treating chronic hepatitis B. By identifying factors that predict treatment response, clinicians can tailor therapy to individual needs, increasing the likelihood of achieving optimal outcomes. This personalized approach is crucial for ensuring that each patient receives the most appropriate care, leading to better outcomes and a higher quality of life.

Dr.Camel's Conclusion

This study, like a well-stocked oasis in a vast desert, provides valuable information to guide the treatment of HBeAg-negative chronic hepatitis B. By understanding the factors that influence treatment response, clinicians can make more informed decisions, ensuring that patients receive the most effective care and improve their chances of overcoming this challenging disease.

Date :
  1. Date Completed 2007-05-29
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

17127704

DOI: Digital Object Identifier

PMC1942152

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.